1. Medtech Insight
  2. >>Business
  3. >>Deals

Boston Scientific Buys Venous Stent-Developer Veniti For $160M

 
• By Reed Miller

Boston Scientific has agreed to pay up to $160m for the remaining 75% of Veniti Inc. that it does not already own. Veniti is a privately held Fremont, Calif. company that has developed and commercialized the Vici venous stent system for treating venous obstructive disease. The transaction price includes $108m upfront and $52m contingent on US FDA approval of Vici.

Business teamwork puzzle pieces.
• Source: shutterstock.com

Following Veniti Inc.'s completion of a PMA application for its Vici venous stent system, Boston Scientific Corp. has agreed to pay $108m upfront, plus $52m in milestones, to acquire the 75% of Veniti that it does not already own, the companies announced Aug. 8.

Boston Scientific first invested in Veniti in 2016 and currently owns 25% of the Fremont, Calif.-based private company. The $52m...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

PFA Market Surges As UK NICE Opens Doors And US FDA Approves Boston, J&J Incremental Innovations

 
• By Natasha Barrow

The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By Marion Webb

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 
• By Natasha Barrow

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

More from Business

Deals Shaping The Medtech And Diagnostics Industries, June 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

Endo Tools, Fujifilm Partner to Fast-Track Endomina Rollout Across MEA Region

 
• By Shubham Singh

CEO Alexandre Chau told Medtech Insight that the Middle East and Africa presented the ideal mix of market potential, physician training opportunities, and regulatory readiness when the company was considering expansion markets beyond Europe and the US.